 | • レポートコード：GIR-203B16267 • 出版社/出版日：GlobalInfoResearch / 2021年12月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、89ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品 |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 癌免疫治療薬市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 GlobalInfoResearchの最新の調査によると、世界の癌免疫治療薬の市場規模は2020年のxxx米ドルから2021年にはxxx米ドルと推定され、2020年から2021年の間にxxx％の変化があります。世界の癌免疫治療薬の市場規模は次の5年間でxxx％のCAGRで成長すると予想されます。 癌免疫治療薬市場は種類と用途によって区分されます。2016年～2026年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメントは次をカバーします。 ・免疫チェックポイント阻害剤、サイトカインベース免疫療法、癌ワクチン、CAR-T細胞療法、その他 用途別セグメントは次のように区分されます。 ・病院、薬局、その他 世界の癌免疫治療薬市場の主要な市場プレーヤーは以下のとおりです。 ・Bristol-Myers Squibb、Merck & Co、Roche AG、AstraZeneca、Sanofi S.A.、Dendreon Pharmaceuticals、Novartis、Gilead Sciences Inc.、Merck KGaA 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計14章あります。 ・第1章では、癌免疫治療薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要な癌免疫治療薬メーカーの企業概要、2019年～2021年までの癌免疫治療薬の価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要な癌免疫治療薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2016年～2026年までの地域別癌免疫治療薬の販売量、売上、成長性を示しています。 ・第5、6章では、2016年～2026年までの癌免疫治療薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2016年～2021年までの世界の主要国での販売量、売上、市場シェア、並びに2021年～2026年までの主要地域での癌免疫治療薬市場予測を収録しています。 ・第12、13、14章では、癌免疫治療薬の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。 ***** 目次(一部) ***** ・市場概要 ・メーカー情報（企業概要、製品概要、販売量、価格、売上）：Bristol-Myers Squibb、Merck & Co、Roche AG、AstraZeneca、Sanofi S.A.、Dendreon Pharmaceuticals、Novartis、Gilead Sciences Inc.、Merck KGaA ・メーカー別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：免疫チェックポイント阻害剤、サイトカインベース免疫療法、癌ワクチン、CAR-T細胞療法、その他 ・用途別分析2016年-2026年：病院、薬局、その他 ・癌免疫治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・癌免疫治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・癌免疫治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・癌免疫治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・癌免疫治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Oncology Immuno Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Oncology Immuno Drug size is estimated to be million in 2021 from USD million in 2020, with a change of % between 2020 and 2021. The global Oncology Immuno Drug market size is expected to grow at a CAGR of % for the next five years.
Market segmentation
Oncology Immuno Drug market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Immune Checkpoint Inhibitors
Cytokine-Based Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy
Other
Market segment by Application can be divided into
Hospitals
Drugstores
Others
The key market players for global Oncology Immuno Drug market are listed below:
Bristol-Myers Squibb
Merck & Co
Roche AG
AstraZeneca
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
Merck KGaA
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Oncology Immuno Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Oncology Immuno Drug, with price, sales, revenue and global market share of Oncology Immuno Drug from 2019 to 2021.
Chapter 3, the Oncology Immuno Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Oncology Immuno Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2016 to 2026.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2026.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Oncology Immuno Drug market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Oncology Immuno Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Oncology Immuno Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Oncology Immuno Drug Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Immune Checkpoint Inhibitors
1.2.3 Cytokine-Based Immunotherapy
1.2.4 Cancer Vaccines
1.2.5 CAR-T Cell Therapy
1.2.6 Other
1.3 Market Analysis by Application
1.3.1 Overview: Global Oncology Immuno Drug Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Others
1.4 Global Oncology Immuno Drug Market Size & Forecast
1.4.1 Global Oncology Immuno Drug Sales in Value (2016-2026))
1.4.2 Global Oncology Immuno Drug Sales in Volume (2016-2026)
1.4.3 Global Oncology Immuno Drug Price by Type (2016-2026) & (US$/Unit)
1.5 Global Oncology Immuno Drug Production Capacity Analysis
1.5.1 Global Oncology Immuno Drug Total Production Capacity (2016-2026)
1.5.2 Global Oncology Immuno Drug Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Oncology Immuno Drug Market Drivers
1.6.2 Oncology Immuno Drug Market Restraints
1.6.3 Oncology Immuno Drug Trends Analysis
2 Manufacturers Profiles
2.1 Bristol-Myers Squibb
2.1.1 Bristol-Myers Squibb Details
2.1.2 Bristol-Myers Squibb Major Business
2.1.3 Bristol-Myers Squibb Oncology Immuno Drug Product and Services
2.1.4 Bristol-Myers Squibb Oncology Immuno Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 Merck & Co
2.2.1 Merck & Co Details
2.2.2 Merck & Co Major Business
2.2.3 Merck & Co Oncology Immuno Drug Product and Services
2.2.4 Merck & Co Oncology Immuno Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 Roche AG
2.3.1 Roche AG Details
2.3.2 Roche AG Major Business
2.3.3 Roche AG Oncology Immuno Drug Product and Services
2.3.4 Roche AG Oncology Immuno Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 AstraZeneca
2.4.1 AstraZeneca Details
2.4.2 AstraZeneca Major Business
2.4.3 AstraZeneca Oncology Immuno Drug Product and Services
2.4.4 AstraZeneca Oncology Immuno Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Sanofi S.A.
2.5.1 Sanofi S.A. Details
2.5.2 Sanofi S.A. Major Business
2.5.3 Sanofi S.A. Oncology Immuno Drug Product and Services
2.5.4 Sanofi S.A. Oncology Immuno Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 Dendreon Pharmaceuticals
2.6.1 Dendreon Pharmaceuticals Details
2.6.2 Dendreon Pharmaceuticals Major Business
2.6.3 Dendreon Pharmaceuticals Oncology Immuno Drug Product and Services
2.6.4 Dendreon Pharmaceuticals Oncology Immuno Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.7 Novartis
2.7.1 Novartis Details
2.7.2 Novartis Major Business
2.7.3 Novartis Oncology Immuno Drug Product and Services
2.7.4 Novartis Oncology Immuno Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.8 Gilead Sciences Inc.
2.8.1 Gilead Sciences Inc. Details
2.8.2 Gilead Sciences Inc. Major Business
2.8.3 Gilead Sciences Inc. Oncology Immuno Drug Product and Services
2.8.4 Gilead Sciences Inc. Oncology Immuno Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.9 Merck KGaA
2.9.1 Merck KGaA Details
2.9.2 Merck KGaA Major Business
2.9.3 Merck KGaA Oncology Immuno Drug Product and Services
2.9.4 Merck KGaA Oncology Immuno Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Oncology Immuno Drug Sales by Manufacturer
3.1 Global Oncology Immuno Drug Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Oncology Immuno Drug Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Oncology Immuno Drug
3.4 Market Concentration Rate
3.4.1 Top 3 Oncology Immuno Drug Manufacturer Market Share
3.4.2 Top 6 Oncology Immuno Drug Manufacturer Market Share
3.5 Global Oncology Immuno Drug Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Oncology Immuno Drug Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Oncology Immuno Drug Market Size by Region
4.1.1 Global Oncology Immuno Drug Sales in Volume by Region (2016-2026)
4.1.2 Global Oncology Immuno Drug Revenue by Region (2016-2026)
4.2 North America Oncology Immuno Drug Revenue (2016-2026)
4.3 Europe Oncology Immuno Drug Revenue (2016-2026)
4.4 Asia-Pacific Oncology Immuno Drug Revenue (2016-2026)
4.5 South America Oncology Immuno Drug Revenue (2016-2026)
4.6 Middle East and Africa Oncology Immuno Drug Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Oncology Immuno Drug Sales in Volume by Type (2016-2026)
5.2 Global Oncology Immuno Drug Revenue by Type (2016-2026)
5.3 Global Oncology Immuno Drug Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Oncology Immuno Drug Sales in Volume by Application (2016-2026)
6.2 Global Oncology Immuno Drug Revenue by Application (2016-2026)
6.3 Global Oncology Immuno Drug Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Oncology Immuno Drug Sales by Type (2016-2026)
7.2 North America Oncology Immuno Drug Sales by Application (2016-2026)
7.3 North America Oncology Immuno Drug Market Size by Country
7.3.1 North America Oncology Immuno Drug Sales in Volume by Country (2016-2026)
7.3.2 North America Oncology Immuno Drug Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Oncology Immuno Drug Sales by Type (2016-2026)
8.2 Europe Oncology Immuno Drug Sales by Application (2016-2026)
8.3 Europe Oncology Immuno Drug Market Size by Country
8.3.1 Europe Oncology Immuno Drug Sales in Volume by Country (2016-2026)
8.3.2 Europe Oncology Immuno Drug Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Oncology Immuno Drug Sales by Type (2016-2026)
9.2 Asia-Pacific Oncology Immuno Drug Sales by Application (2016-2026)
9.3 Asia-Pacific Oncology Immuno Drug Market Size by Region
9.3.1 Asia-Pacific Oncology Immuno Drug Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Oncology Immuno Drug Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Oncology Immuno Drug Sales by Type (2016-2026)
10.2 South America Oncology Immuno Drug Sales by Application (2016-2026)
10.3 South America Oncology Immuno Drug Market Size by Country
10.3.1 South America Oncology Immuno Drug Sales in Volume by Country (2016-2026)
10.3.2 South America Oncology Immuno Drug Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Oncology Immuno Drug Sales by Type (2016-2026)
11.2 Middle East & Africa Oncology Immuno Drug Sales by Application (2016-2026)
11.3 Middle East & Africa Oncology Immuno Drug Market Size by Country
11.3.1 Middle East & Africa Oncology Immuno Drug Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Oncology Immuno Drug Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Oncology Immuno Drug Typical Distributors
12.3 Oncology Immuno Drug Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Oncology Immuno Drug Revenue by Type, (USD Million), 2021-2026
Table 2. Global Oncology Immuno Drug Revenue by Application, (USD Million), 2021-2026
Table 3. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 4. Bristol-Myers Squibb Major Business
Table 5. Bristol-Myers Squibb Oncology Immuno Drug Product and Services
Table 6. Bristol-Myers Squibb Oncology Immuno Drug Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Merck & Co Basic Information, Manufacturing Base and Competitors
Table 8. Merck & Co Major Business
Table 9. Merck & Co Oncology Immuno Drug Product and Services
Table 10. Merck & Co Oncology Immuno Drug Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Roche AG Basic Information, Manufacturing Base and Competitors
Table 12. Roche AG Major Business
Table 13. Roche AG Oncology Immuno Drug Product and Services
Table 14. Roche AG Oncology Immuno Drug Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 16. AstraZeneca Major Business
Table 17. AstraZeneca Oncology Immuno Drug Product and Services
Table 18. AstraZeneca Oncology Immuno Drug Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Sanofi S.A. Basic Information, Manufacturing Base and Competitors
Table 20. Sanofi S.A. Major Business
Table 21. Sanofi S.A. Oncology Immuno Drug Product and Services
Table 22. Sanofi S.A. Oncology Immuno Drug Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Dendreon Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 24. Dendreon Pharmaceuticals Major Business
Table 25. Dendreon Pharmaceuticals Oncology Immuno Drug Product and Services
Table 26. Dendreon Pharmaceuticals Oncology Immuno Drug Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Novartis Basic Information, Manufacturing Base and Competitors
Table 28. Novartis Major Business
Table 29. Novartis Oncology Immuno Drug Product and Services
Table 30. Novartis Oncology Immuno Drug Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Gilead Sciences Inc. Basic Information, Manufacturing Base and Competitors
Table 32. Gilead Sciences Inc. Major Business
Table 33. Gilead Sciences Inc. Oncology Immuno Drug Product and Services
Table 34. Gilead Sciences Inc. Oncology Immuno Drug Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Merck KGaA Basic Information, Manufacturing Base and Competitors
Table 36. Merck KGaA Major Business
Table 37. Merck KGaA Oncology Immuno Drug Product and Services
Table 38. Merck KGaA Oncology Immuno Drug Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 39. Global Oncology Immuno Drug Sales by Manufacturer (2019-2021e) & (K Units)
Table 40. Global Oncology Immuno Drug Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 41. Market Position of Manufacturers in Oncology Immuno Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 42. Global Oncology Immuno Drug Production Capacity by Company, (K Units): 2020 VS 2021
Table 43. Head Office and Oncology Immuno Drug Production Site of Key Manufacturer
Table 44. Oncology Immuno Drug New Entrant and Capacity Expansion Plans
Table 45. Oncology Immuno Drug Mergers & Acquisitions in the Past Five Years
Table 46. Global Oncology Immuno Drug Sales by Region (2016-2021e) & (K Units)
Table 47. Global Oncology Immuno Drug Sales by Region (2021-2026) & (K Units)
Table 48. Global Oncology Immuno Drug Revenue by Region (2016-2021e) & (USD Million)
Table 49. Global Oncology Immuno Drug Revenue by Region (2021-2026) & (USD Million)
Table 50. Global Oncology Immuno Drug Sales by Type (2016-2021e) & (K Units)
Table 51. Global Oncology Immuno Drug Sales by Type (2021-2026) & (K Units)
Table 52. Global Oncology Immuno Drug Revenue by Type (2016-2021e) & (USD Million)
Table 53. Global Oncology Immuno Drug Revenue by Type (2021-2026) & (USD Million)
Table 54. Global Oncology Immuno Drug Price by Type (2016-2021e) & (US$/Unit)
Table 55. Global Oncology Immuno Drug Price by Type (2021-2026) & (US$/Unit)
Table 56. Global Oncology Immuno Drug Sales by Application (2016-2021e) & (K Units)
Table 57. Global Oncology Immuno Drug Sales by Application (2021-2026) & (K Units)
Table 58. Global Oncology Immuno Drug Revenue by Application (2016-2021e) & (USD Million)
Table 59. Global Oncology Immuno Drug Revenue by Application (2021-2026) & (USD Million)
Table 60. Global Oncology Immuno Drug Price by Application (2016-2021e) & (US$/Unit)
Table 61. Global Oncology Immuno Drug Price by Application (2021-2026) & (US$/Unit)
Table 62. North America Oncology Immuno Drug Sales by Country (2016-2021e) & (K Units)
Table 63. North America Oncology Immuno Drug Sales by Country (2021-2026) & (K Units)
Table 64. North America Oncology Immuno Drug Revenue by Country (2016-2021e) & (USD Million)
Table 65. North America Oncology Immuno Drug Revenue by Country (2021-2026) & (USD Million)
Table 66. North America Oncology Immuno Drug Sales by Type (2016-2021e) & (K Units)
Table 67. North America Oncology Immuno Drug Sales by Type (2021-2026) & (K Units)
Table 68. North America Oncology Immuno Drug Sales by Application (2016-2021e) & (K Units)
Table 69. North America Oncology Immuno Drug Sales by Application (2021-2026) & (K Units)
Table 70. Europe Oncology Immuno Drug Sales by Country (2016-2021e) & (K Units)
Table 71. Europe Oncology Immuno Drug Sales by Country (2021-2026) & (K Units)
Table 72. Europe Oncology Immuno Drug Revenue by Country (2016-2021e) & (USD Million)
Table 73. Europe Oncology Immuno Drug Revenue by Country (2021-2026) & (USD Million)
Table 74. Europe Oncology Immuno Drug Sales by Type (2016-2021e) & (K Units)
Table 75. Europe Oncology Immuno Drug Sales by Type (2021-2026) & (K Units)
Table 76. Europe Oncology Immuno Drug Sales by Application (2016-2021e) & (K Units)
Table 77. Europe Oncology Immuno Drug Sales by Application (2021-2026) & (K Units)
Table 78. Asia-Pacific Oncology Immuno Drug Sales by Region (2016-2021e) & (K Units)
Table 79. Asia-Pacific Oncology Immuno Drug Sales by Region (2021-2026) & (K Units)
Table 80. Asia-Pacific Oncology Immuno Drug Revenue by Region (2016-2021e) & (USD Million)
Table 81. Asia-Pacific Oncology Immuno Drug Revenue by Region (2021-2026) & (USD Million)
Table 82. Asia-Pacific Oncology Immuno Drug Sales by Type (2016-2021e) & (K Units)
Table 83. Asia-Pacific Oncology Immuno Drug Sales by Type (2021-2026) & (K Units)
Table 84. Asia-Pacific Oncology Immuno Drug Sales by Application (2016-2021e) & (K Units)
Table 85. Asia-Pacific Oncology Immuno Drug Sales by Application (2021-2026) & (K Units)
Table 86. South America Oncology Immuno Drug Sales by Country (2016-2021e) & (K Units)
Table 87. South America Oncology Immuno Drug Sales by Country (2021-2026) & (K Units)
Table 88. South America Oncology Immuno Drug Revenue by Country (2016-2021e) & (USD Million)
Table 89. South America Oncology Immuno Drug Revenue by Country (2021-2026) & (USD Million)
Table 90. South America Oncology Immuno Drug Sales by Type (2016-2021e) & (K Units)
Table 91. South America Oncology Immuno Drug Sales by Type (2021-2026) & (K Units)
Table 92. South America Oncology Immuno Drug Sales by Application (2016-2021e) & (K Units)
Table 93. South America Oncology Immuno Drug Sales by Application (2021-2026) & (K Units)
Table 94. Middle East & Africa Oncology Immuno Drug Sales by Country (2016-2021e) & (K Units)
Table 95. Middle East & Africa Oncology Immuno Drug Sales by Country (2021-2026) & (K Units)
Table 96. Middle East & Africa Oncology Immuno Drug Revenue by Country (2016-2021e) & (USD Million)
Table 97. Middle East & Africa Oncology Immuno Drug Revenue by Country (2021-2026) & (USD Million)
Table 98. Middle East & Africa Oncology Immuno Drug Sales by Type (2016-2021e) & (K Units)
Table 99. Middle East & Africa Oncology Immuno Drug Sales by Type (2021-2026) & (K Units)
Table 100. Middle East & Africa Oncology Immuno Drug Sales by Application (2016-2021e) & (K Units)
Table 101. Middle East & Africa Oncology Immuno Drug Sales by Application (2021-2026) & (K Units)
Table 102. Direct Channel Pros & Cons
Table 103. Indirect Channel Pros & Cons
Table 104. Oncology Immuno Drug Typical Distributors
Table 105. Oncology Immuno Drug Typical Customers
List of Figures
Figure 1. Oncology Immuno Drug Picture
Figure 2. Global Oncology Immuno Drug Sales Market Share by Type in 2020
Figure 3. Immune Checkpoint Inhibitors
Figure 4. Cytokine-Based Immunotherapy
Figure 5. Cancer Vaccines
Figure 6. CAR-T Cell Therapy
Figure 7. Other
Figure 8. Global Oncology Immuno Drug Sales Market Share by Application in 2020
Figure 9. Hospitals
Figure 10. Drugstores
Figure 11. Others
Figure 12. Global Oncology Immuno Drug Market Size, (USD Million) & (K Units): 2020 VS 2021 VS 2026
Figure 13. Global Oncology Immuno Drug Market Size and Forecast (2016-2026) & (USD Million)
Figure 14. Global Oncology Immuno Drug Sales (2016-2026) & (K Units)
Figure 15. Global Oncology Immuno Drug Price by Type (2016-2026) & (US$/Unit)
Figure 16. Global Oncology Immuno Drug Production Capacity (2016-2026) & (K Units)
Figure 17. Global Oncology Immuno Drug Production Capacity by Geographic Region: 2020 VS 2021
Figure 18. Oncology Immuno Drug Market Drivers
Figure 19. Oncology Immuno Drug Market Restraints
Figure 20. Oncology Immuno Drug Market Trends
Figure 21. Global Oncology Immuno Drug Sales Market Share by Manufacturer in 2020
Figure 22. Global Oncology Immuno Drug Revenue Market Share by Manufacturer in 2020
Figure 23. Oncology Immuno Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 24. Top 3 Oncology Immuno Drug Manufacturer (Revenue) Market Share in 2020
Figure 25. Top 6 Oncology Immuno Drug Manufacturer (Revenue) Market Share in 2020
Figure 26. Global Oncology Immuno Drug Sales Market Share by Region (2016-2026)
Figure 27. Global Oncology Immuno Drug Revenue Market Share by Region (2016-2026)
Figure 28. North America Oncology Immuno Drug Revenue (2016-2026) & (USD Million)
Figure 29. Europe Oncology Immuno Drug Revenue (2016-2026) & (USD Million)
Figure 30. Asia-Pacific Oncology Immuno Drug Revenue (2016-2026) & (USD Million)
Figure 31. South America Oncology Immuno Drug Revenue (2016-2026) & (USD Million)
Figure 32. Middle East & Africa Oncology Immuno Drug Revenue (2016-2026) & (USD Million)
Figure 33. Global Oncology Immuno Drug Sales Market Share by Type (2016-2026)
Figure 34. Global Oncology Immuno Drug Revenue Market Share by Type (2016-2026)
Figure 35. Global Oncology Immuno Drug Price by Type (2016-2026) & (US$/Unit)
Figure 36. Global Oncology Immuno Drug Sales Market Share by Application (2016-2026)
Figure 37. Global Oncology Immuno Drug Revenue Market Share by Application (2016-2026)
Figure 38. Global Oncology Immuno Drug Price by Application (2016-2026) & (US$/Unit)
Figure 39. North America Oncology Immuno Drug Sales Market Share by Type (2016-2026)
Figure 40. North America Oncology Immuno Drug Sales Market Share by Application (2016-2026)
Figure 41. North America Oncology Immuno Drug Sales Market Share by Country (2016-2026)
Figure 42. North America Oncology Immuno Drug Revenue Market Share by Country (2016-2026)
Figure 43. United States Oncology Immuno Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Canada Oncology Immuno Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Mexico Oncology Immuno Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Europe Oncology Immuno Drug Sales Market Share by Type (2016-2026)
Figure 47. Europe Oncology Immuno Drug Sales Market Share by Application (2016-2026)
Figure 48. Europe Oncology Immuno Drug Sales Market Share by Country (2016-2026)
Figure 49. Europe Oncology Immuno Drug Revenue Market Share by Country (2016-2026)
Figure 50. Germany Oncology Immuno Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. France Oncology Immuno Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. United Kingdom Oncology Immuno Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Russia Oncology Immuno Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Italy Oncology Immuno Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Asia-Pacific Oncology Immuno Drug Sales Market Share by Region (2016-2026)
Figure 56. Asia-Pacific Oncology Immuno Drug Sales Market Share by Application (2016-2026)
Figure 57. Asia-Pacific Oncology Immuno Drug Sales Market Share by Region (2016-2026)
Figure 58. Asia-Pacific Oncology Immuno Drug Revenue Market Share by Region (2016-2026)
Figure 59. China Oncology Immuno Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Japan Oncology Immuno Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Korea Oncology Immuno Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. India Oncology Immuno Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Southeast Asia Oncology Immuno Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Australia Oncology Immuno Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. South America Oncology Immuno Drug Sales Market Share by Type (2016-2026)
Figure 66. South America Oncology Immuno Drug Sales Market Share by Application (2016-2026)
Figure 67. South America Oncology Immuno Drug Sales Market Share by Country (2016-2026)
Figure 68. South America Oncology Immuno Drug Revenue Market Share by Country (2016-2026)
Figure 69. Brazil Oncology Immuno Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Argentina Oncology Immuno Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Middle East & Africa Oncology Immuno Drug Sales Market Share by Type (2016-2026)
Figure 72. Middle East & Africa Oncology Immuno Drug Sales Market Share by Application (2016-2026)
Figure 73. Middle East & Africa Oncology Immuno Drug Sales Market Share by Country (2016-2026)
Figure 74. Middle East & Africa Oncology Immuno Drug Revenue Market Share by Country (2016-2026)
Figure 75. Turkey Oncology Immuno Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Egypt Oncology Immuno Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Saudi Arabia Oncology Immuno Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. South Africa Oncology Immuno Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. Sales Channel: Direct Channel vs Indirect Channel
Figure 80. Methodology
Figure 81. Research Process and Data Source
口内潰瘍治療薬のグローバル市場 2021年：企業別、地域別、種類・用途別 The Mouth Ulcer Treatment Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regu…- リンパ腫治療薬のグローバル市場 2021年：企業別、地域別、種類・用途別 The Lymphoma Treatment Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulat…
- ジフルプレドナート薬のグローバル市場 2021年：企業別、地域別、種類・用途別 The Difluprednate Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations,…
- 筋緊張性ジストロフィー治療薬のグローバル市場 2021年：企業別、地域別、種類・用途別 The Myotonic Dystrophy Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulat…
- シタラビン注射のグローバル市場 2021年：企業別、地域別、種類・用途別 The Cytarabine Injection market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulation…